Lower relapse incidence with haploidentical versus matched sibling or unrelated donor hematopoietic cell transplantation for core-binding factor AML patients in CR2: A study from the Global Committee and the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation

Allogeneic hematopoietic cell transplantation (allo-HCT) is recommended for core-binding factor mutated (CBF) AML patients achieving second complete remission (CR2). However, approximately 20% of patients may relapse after transplant and donor preference remains unclear. We compared in this EBMT global multicenter registry-based analysis the allo-HCT outcomes using either haploidentical (Haplo), matched siblings donors (MSD), or 10/10 matched unrelated donors (MUD). Data from 865 de novo adult CBF AML patients in CR2 receiving allo-HCT in 227 EBMT centers from 2010 to 2022 were analyzed, in which 329 MSD, 374 MUD, and 162 Haplo-HCTs were included. For the entire cohort, 503 (58%) patients were inv(16)/CBFB-MYH11 and 362 patients (42%) were t(8;21)/RUNX1-RUNX1T1 AML. On multivariate analysis, Haplo-HCT was associated with a lower Relapse Incidence (RI) compared to either MSD (hazard ratio [HR] = 0.56, 95% CI 0.32-0.97; p < .05) or MUD (HR = 0.57, 95% CI: 0.33-0.99, p < .05). No significant difference was observed among the 3 types of donors on LFS, OS and GRFS. CBF-AML with t(8;21) was associated with both higher RI (HR = 1.79, 95% CI 1.3-2.47; p < .01) and higher NRM (HR = 1.58, 95% CI 1.1-2.27; p < .01) than CBF-AML with inv(16), which led to worse LFS, OS and GRFS. To conclude, for CBF-AML patients in CR2, Haplo-HCTs were associated with a lower RI compared to MSD and MUD allo-HCTs. There was no difference on LFS, OS or GRFS. CBF AML patients with inv(16) had a better progonosis than those with t(8;21) after allo-HCT in CR2.

Aligning quality of life and guidelines for off-label psychotropic drugs in adults with intellectual disabilities and challenging behaviour

Introduction

Adults with intellectual disabilities have an increased vulnerability to mental health problems and challenging behaviour. In addition to psychotherapeutic or psychoeducational methods, off-label pharmacotherapy, is a commonly used treatment modality.

Objective

The aim of this study was to establish evidence-based guideline recommendations for the responsible prescription of off-label psychotropic drugs, in relation to Quality of Life (QoL).

Method

A list of guidelines was selected, and principles were established based on international literature, guideline review and expert evaluation. The Delphi method was used to achieve consensus about guideline recommendations among a 58-member international multidisciplinary expert Delphi panel. Thirty-three statements were rated on a 5-point Likert-scale, ranging from totally disagree to totally agree, in consecutive Delphi rounds. When at least 70% of the participants agreed (score equal or higher than 4), a statement was accepted . Statements without a consensus were adjusted between consecutive Delphi rounds based on feedback from the Delphi panel.

Results

Consensus was reached on 4 general:the importance of non-pharmaceutical treatments, comprehensive diagnostics and multidisciplinary treatment. Consensus was reached in 4 rounds on 29 statements. No consensus was reached on 4 statements concerning: freedom-restricting measures, the treatment plan, the evaluation of the treatment plan, and the informed consent.

Conclusion

The study led to recommendations and principles for the responsible prescription - aligned with the QoL perspective - of off-label psychotropic drugs for adults with intellectual disabilities and challenging behaviour. Extensive discussion is needed regarding the issues on which there was no consensus to furthering the ongoing development of this guideline.

Quelles sont les conséquences de l’épidémie COVID-19 sur l’organisation des soins ?

Introduction

Le 30/01/2020, l’OMS déclare une urgence de Santé Publique de portée internationale suite à l’épidémie de COVID-19. Les conséquences des épidémies sont nombreuses, aussi bien pour les patients que pour l’ensemble du système de santé. Cette étude a pour but d’évaluer les conséquences de l’épidémie COVID-19 sur l’organisation des soins à l’échelle hospitalière.

Matériels et méthodes

Nous avons récolté des données sur la réponse épidémique dans un hôpital prenant en charge des patients infectés par le SARS-CoV-2 à l’aide de plusieurs sources : entretiens individuels semi-structurés, périodes d’observation ethnographique in situ et analyse documentaire. Les entretiens ont été réalisés auprès des différents professionnels de l’hôpital. Les différents points de vue et niveaux organisationnels ont été envisagés lors des entretiens à l’aide d’une approche adaptative et itérative. Les entretiens étaient enregistrés, transcrits et codés à l’aide du logiciel NVivo 12. Les données qualitatives ont été analysées par une analyse thématique inductive.

Résultats

Nous avons réalisé 37 entretiens avec des personnels de santé (infirmier/e/s, médecins, aides-soignant/e/s, manipulateurs radiologiques, cadres de santé) dans plusieurs services (urgences, maladies infectieuses, réanimation, chirurgie cardiaque, équipe d’hygiène) et avec des personnels administratifs (personnel de sécurité, de logistique, de communication et de direction). Nous avons également collecté plus de 100 heures d’observation ethnographique. Concernant la réponse à l’épidémie, nous avons identifié des éléments facilitateurs comme la gestion de cas suspects pour les épidémies antérieures (MERS-CoV et Ebola), la réalisation d’exercices réguliers par l’équipe d’hygiène, et l’existence préalable de protocoles mais aussi des problèmes non anticipés comme la gestion des déchets à risques biologiques, des difficultés à recruter des infirmiers intérimaires ou la pression médiatique et les rumeurs. Les conséquences de l’épidémie ont été directes ; réorganisation du service de maladies infectieuses, de réanimation médicale et de virologie mais également indirectes ; diminution de l’activité de l’équipe mobile d’infectiologie et des activités d’enseignement, inquiétude des patients non concernés et annulation de rendez-vous. Ont été soulignés par les participants l’importance de maintenir la cohésion des équipes entre personnels travaillant auprès de patients infectés par le SARS-CoV-2 et personnels non impliqués, d’intégrer de façon harmonieuse la recherche clinique dans la prise en charge médicale et de réaliser un travail de veille bibliographique en temps réel afin d’actualiser la prise en charge des cas possibles et confirmés.

Conclusion

L’épidémie COVID-19 a eu de nombreuses conséquences sur l’organisation aussi bien des services médicaux concernés que des services non directement impliqués et des services administratifs. Cette étude permet d’identifier des pistes d’amélioration pour la réponse épidémique.

No Difference in the Phenotypic Expression of Frailty among Elderly Patients Recently Diagnosed with Cancer Vs Cancer Free Patients

OBJECTIVES

To examine frailty determinants differences in patients with a recent diagnosis of cancer compared to non-cancer patients among older adult. Revealing those differences will allow us to individualize the exact frailty management in those patients diagnosed with cancer.

DESIGN

This is an observational cross-sectional, monocentric study.

SETTING

Patients were evaluated at the Geriatric Frailty Clinic (GFC), in the Toulouse University Hospital, France, between October 2011 and February 2016.

PARTICIPANTS

1996 patients aged 65 and older were included (1578 patients without cancer and 418 patients with solid and hematological cancer recently diagnosed).

MEASUREMENTS

Frailty was established according to the frailty phenotype. The frailty phenotype measures five components of frailty: weight loss, exhaustion, low physical activity, weakness and slow gait. Frailty phenotype was categorized as robust, pre-frail and frail.

RESULTS

In a multinomial logistic regression, cancer, compared to the non-cancer group, is not associated with an increased likelihood of being classified as pre frail (RRR 0.9, 95% CI [0.5 ; 1.6 ], p 0.9) or frail (RRR 1.2, 95% CI [0.7 ; 2.0], p 0.4) rather than robust. When considering each Fried criterion, a significant higher odd of weight loss was observed in older patients with cancer compared to the non-cancer patients (OR 2.3, 95% CI [1.8; 3.0], p <0.001) but no statistically significant differences was found among the four other Fried criteria. Sensitivity analysis on the frailty index showed that cancer was not associated with a higher FI score compared to non-cancer (β 0.002, 95%CI [-0.009; 0.01], p 0.6).

CONCLUSION

In this real-life study evaluating elderly patients with and without cancer, we didn't confirm our hypothesis, in fact we found that cancer was not associated with frailty severity using both a phenotypic model and a deficit accumulation approach. Cancer may contribute, at least additively, to the development of frailty, like any other comorbidity, rather than a global underlying condition of vulnerability.

Drug Prescription Including Interactions with Anticancer Treatments in the Elderly: A Global Approach

BACKGROUND

Consequences of inappropriate prescriptions and polymedication in patients suffering from cancer are beginning to be well documented. However, the methods used to evaluate these consequences are often discussed. Few studies evaluate the risk of interaction with anticancer drugs in elderly patients suffering from cancer.

OBJECTIVES

To describe the prevalence (i) of polypharmacy, (ii) of potentially inappropriate drug prescriptions and (iii) of drug interactions involving anticancer treatments, using a multiple reference tools.

DESIGN

A retrospective, cross-sectional, multicenter study performed from January to December 2012.

PARTICIPANTS

Patients aged 65 years or older suffering from cancer presented at the oncogeriatric multidisciplinary meeting.

MEASUREMENTS

Polymedication (>6 drugs), potentially inappropriate prescriptions and drug interactions involving anticancer treatment were analyzed in combination with explicit and implicit criteria within a global approach.

RESULTS

Among the 106 patients included in this study, polypharmacy was present in 60.4% of cases, potentially inappropriate drug prescription in 63.1% and drug interactions in 16% of case, of which 47% involved anti-cancer treatments. Twenty-seven major drug interactions were identified and eight interactions involved chemotherapy.

CONCLUSION

Polymedication, inappropriate prescribing and drug interactions involving anti-cancer drugs are common and largely underestimated in elderly cancer patients.

Body Composition and Anti-Neoplastic Treatment in Adult and Older Subjects - A Systematic Review

BACKGROUND

The estimation of the risk of poor tolerance and overdose of antineoplastic agents protocols represents a major challenge in oncology, particularly in older patients. We hypothesize that age-related modifications of body composition (i.e. increased fat mass and decreased lean mass) may significantly affect tolerance to chemotherapy.

METHOD

We conducted a systematic review for the last 25 years (between 1990 and 2015), using US National library of Medicine Medline electronic bibliographic database and Embase database of cohorts or clinical trials exploring (i) the interactions of body composition (assessed by Dual X-ray Absorptiometry, Bioelectrical Impedance Analyses, or Computerized Tomography) with pharmacokinetics parameters, (ii) the tolerance to chemotherapy, and (iii) the consequences of chemotherapies or targeted therapies on body composition.

RESULTS

Our search identified 1504 articles. After a selection (using pre-established criteria) on titles and abstract, 24 original articles were selected with 3 domains of interest: impact of body composition on pharmacokinetics (7 articles), relationship between body composition and chemotoxicity (14 articles), and effect of anti-cancer chemotherapy on body composition (11 articles). The selected studies suggested that pharmacokinetic was influenced by lean mass, that lower lean mass could be correlated with toxicity, and that sarcopenic patients experienced more toxicities that non-sarcopenic patients. Regarding fat mass, results were less conclusive. No studies specifically explored the topic of body composition in older cancer patients.

CONCLUSIONS

Plausible pathophysiological pathways linking body composition, toxicity, and pharmacokinetics are sustained by the actual review. However, despite the growing number of older cancer patients, our review highlighted the lack of specific studies in the field of anti-neoplastic agents toxicity regarding body composition conducted in elderly.

Impact of an oncogeriatric consulting team on therapeutic decision-making

Increased life expectancy and cancer incidence imply the need to develop a specialized care policy for elderly patients with cancer. We created an oncogeriatric consulting team (OGCT) in Toulouse University Hospital to carry out comprehensive gerontological assessment at the bedside of hospitalized patients. We analyze the impact on the final cancer treatment decision of this mobile geriatric assessment. We carried out a descriptive, retrospective real-life analysis of a patient cohort over a two-year period. The OGCT assessed 124 patients, of whom the majority were women (54.8%), median age 81 years, living at home (95.2%) and with family caregivers (86.5%). Nearly all were frail (96.7% according to the classification of Balducci and colleagues) and 3.2% were vulnerable. The team's decisions were analyzed for patients who had not yet been treated (n=107). After analysis, the team's proposal was in line with the initial cancer treatment plan in 68.2% of cases (n=73). In cases where there was a disagreement, the final decision was in line with the mobile team's proposal in 17.75% of 107 patients (n=19). The decision of the team was followed more often when their assessment proposed strictly palliative treatment. The decision to give elderly patients specific cancer treatment seems in our experience rather to be a matter for the oncologists, and is not very susceptible to modification by geriatric opinion. On the other hand, the geriatrician appears to be more credible and his/her opinion more likely to be followed when the patient is considered too frail and less aggressive, or even exclusively palliative, treatment is proposed.

Reducing "iatrogenic disability" in the hospitalized frail elderly

BACKGROUND

Hospitalization is the first cause of functional decline in the elderly: 30 to 60% of elderly patients lose some independence in basic activities of daily living (ADL) during a stay in hospital. This loss of independence results from the acute condition that led to admission, but is also related to the mode of management.

OBJECTIVE

This paper is a review of the literature on functional decline in elderly hospitalized patients. It is the first stage in a project aiming to prevent dependence that is induced during the course of care.

METHODS

During a 2-day workshop in Monaco, a task force of 20 international experts discussed and defined the concept of "iatrogenic disability".

RESULTS

1- "Iatrogenic disability" was defined by the task force as the avoidable dependence which often occurs during the course of care. It involves three components that interact and have a cumulative effect: a) the patient's pre-existing frailty, b) the severity of the disorder that led to the patient's admission, and lastly c) the hospital structure and the process of care. 2- The prevention of "iatrogenic disability" involves successive stages. - becoming aware that hospitalization may induce dependence. Epidemiological studies have identified at-risk populations by the use of composite scores (HARP, ISAR, SHERPA, COMPRI, etc). - considering that functional decline is not a fatality. Quality references have already been defined. Interventions to prevent dependence in targeted populations have been set up: simple geriatric consultation teams, single-factor interventions (aimed for example at mobility, delirium, iatrogenic disorders) or multidomain interventions (such as GEM and ACE units, HELP, Fast Track, NICHE). These interventions are essentially centered on the patient's frailty and have limited results, as they take little account of the way the institution functions, which is not aimed at prevention of functional decline. The process of care reveals shortcomings: lack of geriatric knowledge, inadequate evaluation and management of functional status. The group suggests that interventions must not only identify at-risk patients so that they may benefit from specialized management, but they must also target the hospital structure and the process of care. This requires a graded "quality approach" and rethinking of the organization of the hospital around the elderly person.

[Pharmacists' role in smoking cessation activities in Alsace]

In May 1999, France launched a plan to implement a range of tobacco control measures focusing on reducing tobacco use. This study evaluated two professional assistance measures for smoking cessation included in the plan: the over-the-counter sale of nicotine substitutes and replacement therapies and pharmacist training. The article describes the role of pharmacies in smoking cessation and analyses the impact of training on professional practices. The survey was conducted in the year 2000 through a mail poll sent to a random representative sample of 290 pharmacies in the French region of Alsace selected from the Ministry of Health's FINESS database. The cross-sectional survey requested data on the pharmacy and its staff, as well as its role in tobacco prevention and its practices regarding individual smoking cessation interventions (capacity to provide assistance once information is obtained on the patient's smoking status, assessment of the patient's tobacco dependence and their will to quit smoking, initial prescription of a nicotine substitute, and provision of practical advice on maintaining smoking cessation and medical care recourse). Among a total of 82 respondents, 85% proclaimed having provided smoking cessation activities and 37% had undergone training. All of the pharmacies had been declared as tobacco prevention areas. For the pharmacies offering smoking cessation assistance, the methods and activities were in accordance with best practice standards. A comparison between the group of trained pharmacists and those who were untrained did not show any significant difference for the items concerning professional practice. In spite of certain barriers linked to pharmaceutical practice, improvements in the quality of smoking cessation assistance activities provided by pharmacists are possible, such as providing confidential space to advise the client, knowing when referral to a doctor is necessary, and organising personalized follow-up according to the customer's needs.